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Abstract Hypoglycemia is a common and serious problem
among patients with type 1 diabetes receiving treatment with
insulin. Clinical studies have demonstrated that hypoglycemic
edema is involved in the initiation of hypoglycemic brain
damage. However, the mechanisms of this edema are poorly
understood. Vascular endothelial growth factor (VEGF), a po-
tent regulator of blood vessel function, has been observed an
important candidate hormone induced by hypoglycemia to
protect neurons by restoring plasma glucose. Whether
VEGF has a protective effect against hypoglycemia-induced
damage in brain endothelial cells is still unknown. To investi-
gate the effects of hypoglycemia on cerebral microvascular
endothelial cells and assess the protective effect of exogenous
VEGF on endothelial cells during hypoglycemia, confluent
monolayers of the brain endothelial cell line bEnd.3 were
treated with normal (5.5 mM glucose), hypoglycemic (0,
0.5, 1 mM glucose) medium or hypoglycemic medium in
the presence of VEGF. The results clearly showed that hypo-
glycemia significantly downregulated the expression of
claudin-5 in bEnd.3 cells, without affecting ZO-1 and
occ lud in express ion and d is t r ibu t ion . Bes ides ,
transendothelial permeability significantly increased under
hypoglycemic conditions compared to that under control con-
ditions. Moreover, the hypoglycemic medium in presence of
VEGF decreased endothelial permeability via the inhibition of
claudin-5 degradation and improved hypoglycemia-induced
cell toxicity. Furthermore, Glucose transporter-1 (Glut-1)
and apoptosis regulator Bcl-2 expression were significantly
upregulated. Taken together, hypoglycemia can significantly
increase paraendocellular permeability by downregulating
claudin-5 expression.We further showed that VEGF protected
brain endothelial cells against hypoglycemia by enhancing
glucose passage, reducing endothelial cell death, and amelio-
rating paraendocellular permeability.
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Introduction
Hypoglycemia is one of the most common side effects in the
treatment of diabetes, which can lead to recurrent morbidity
and sometimes fatality. Glucose is the main energy substrate
necessary for normal brain activity. Deficiencies in brain glu-
cose (hypoglycemia) can immediately lead to mild brain dys-
function or even irreversible brain damage (Yun and Ko
2015). Three large clinical trials, Action to Control
Cardiovascular Risk in Diabetes (ACCORD), Action in dia-
betes and Vascular Disease (ADVANCE), and the Veterans
Affairs Diabetes Trial, have revealed that episodes of severe
hypoglycemia were associated with an increased risk of sub-
sequent mortality and morbidity (Bonds et al. 2010). In gen-
eral, hypoglycemia occurs commonly in patients with both
type 1 and type 2 diabetes. In a prospective survey, 85.3 and
43.6 % of patients with type 1 and type 2 diabetes, respective-
ly, reported experiencing at least one hypoglycemia event over
30 days, while 13.4 and 6.4 %, respectively, reported at least
one episode of severe hypoglycemia (Cariou et al. 2014). A
recent epidemiological study reported that 84 % of patients
with type 2 diabetes experienced at least one hypoglycemic
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event, and that 42 % of the hypoglycemic episodes were
asymptomatic (Wendel et al. 2014). Moreover, recurrent
mild/moderate hypoglycemia is more common and may have
more serious clinical threats, because it can induce maladap-
tive responses that obscure the symptoms of hypoglycemia
(hypoglycemia unawareness), diminishes counter-regulatory
effects to subsequent hypoglycemia, and eventually jeopar-
dize patients’ safety (Cryer 2004). Recent studies demonstrat-
ed that recurrent mild/moderate hypoglycemia affects brain
function in terms of causing cognitive dysfunction (Schultes
et al. 2005), depression and anxiety (Wild et al. 2007). Severe
hypoglycemia may result in cognitive impairment, coma, sei-
zures and even death. However, despite being a more severe
clinical event, hypoglycemia has received much less attention
from medical workers and patients than hyperglycemia.
The blood–brain barrier (BBB), which maintains homeo-
stasis in brain tissues, plays an important role in hypoglycemic
brain damage. It is well known that the BBB is maintained
primarily by tight junctions (TJs) between brain microvascular
endothelial cells (Zlokovic 2008). TJs are composed of trans-
membrane proteins, including claudins, occludin and junc-
tional adhesion molecule-1 (JAM-1), and peripheral mem-
brane proteins in the zonula occludens family (ZO-1, ZO-2,
and others), which prevent the infiltration of substances from
the bloodstream into the brain. Therefore, in this study, we
attempt to investigate whether hypoglycemia induces cerebral
endothelial dysfunction by regulating claudin-5, occluding
and ZO-1.
VEGF is an endothelial specific mitogen, a potent mediator
of angiogenesis (Medinger and Passweg 2014), and an en-
hancer of vascular permeability (Brkovic and Sirois 2007).
VEGF regulates blood vessel growth, and has been implicated
in neuroprotection, neurogenesis, neuronal patterning, glial
growth (Wuestefeld et al. 2012), and endothelial cell resis-
tance to death (Byeon et al. 2010; Park et al. 2001). Studies
have shown that hypoglycemia dramatically induces VEGF
mRNA expression in various cells (Textor et al. 2006; Park
et al. 2001). Further, VEGF treatment in ischemic rats signif-
icantly improves neurologic recovery (Dzietko et al. 2013).
However, the long-term effects of VEGF treatment in hypo-
glycemic brain endothelial cells are unclear. In the present
study, we investigated the protective effects of abluminal ap-
plication of VEGF during hypoglycemia. Interestingly, long-
term abluminal VEGF treatment did not aggravate endothelial
permeability.
To elucidate the underlying mechanism regulating BBB
permeability during hypoglycemia and the potential role of
exogenous VEGF in protecting brain endothelial cells against
hypoglycemia, we established an in vitro BBB model using
mouse brain microvascular endothelial cells (bEnd.3) which
were cultured in normal glucose (5.5 mM glucose) or low
glucose (0, 0.5, or 1 mM glucose) for varying times. This
was done in the hope of mimicking clinical hypoglycemia
conditions, considering that brain glucose concentrations ap-
proaches zero when blood glucose concentrations falls below
2 mM (Choi et al. 2001), and within 24 h of hypoglycemic
duration was used in many studies (Merino et al. 2014; Sajja
et al. 2014).
Materials and methods
Cell culture and treatments
Immortalized mouse bEnd.3 cells were purchased from the
American Type Culture Collection (ATCC). The cells were
seeded on 12-well glass slides for immunofluorescence stud-
ies, 12-well Transwell inserts (0.4 μm pore/12 mm diameter,
Corning) for endothelial permeability, 24-well plates to ana-
lyze cell viability, or in 6-well plates for western blot studies.
Cell cultures were incubated in complete Dulbecco’s modified
Eagle’s medium (DMEM; Gibco) containing 5.5 mM glucose
supplemented with 10 % fetal bovine serum and 1 %
penicillin-streptomycin in a humidified incubator at 37 °C in
an atmosphere of 5 % CO2 and 95 % air. Culture medium was
replaced every other day until the bEnd.3 monolayer reached
confluence (2–3 d). Cells were used between passages 3 and
15 in all experiments.
For hypoglycemic challenges, confluent bEnd.3 cells were
cultured in normal growth medium for 3 d, followed by cul-
turing in normal glucose (5.5 mM glucose) or low glucose (0,
0.5, or 1 mMglucose) for varying times. In some experiments,
hypoglycemic cells were treated with various VEGF concen-
trations for 24 h.
Western blotting
bEnd.3 cells were lysed in radio immunoprecipitation (RIPA)
buffer (50 mMTris, pH 7.4, 150 mMNaCl, 1 %NP-40, 0.5 %
sodium deoxycholate, 0.1% SDS, and 1mMEDTA) (Thermo
Fisher Scientific, USA), supplemented with 1 % phosphatase
inhibitor cocktail and protease inhibitor cocktail (Thermo
Fisher Scientific, USA). Protein concentrations were estimat-
ed with a BCA protein assay kit (Thermo Fisher Scientific,
USA). Equal amounts of protein were loaded and separated by
SDS-PAGE gel electrophoresis. Proteins were transferred on-
to nitrocellulose membranes. Next, the membranes were
blocked for 1 h in 5 % non-fat dry skim milk prepared in
TBS-T buffer (10 mM Tris–HCl, 150 mM NaCl, and 0.1 %
Tween-20), and incubated with primary antibodies targeting
claudin-5 (diluted 1:500, Invitrogen), ZO-1 (diluted 1:500,
Invitrogen), occludin (diluted 1:500, Invitrogen), or Glut-1
(diluted 1:500, Santa Cruz) in 5 % BSA TBS-T overnight at
4 °C. The blots were then incubated with the respective anti-
rabbit or anti-mouse secondary antibodies for 1 h at room
temperature (RT). After washing with TBS-T, bands were
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detected using an infrared scanner (Odyssey, LI-COR
Bioscience, Lincoln, NE, USA).β-Actin served as the internal
control. Western blots were repeated at least three times for
each sample.
Na-F permeability assay
Endothelial permeability was measured by assessing the
transendothelial transport of Na-F (376 Da) as previously
described (Dohgu et al. 2004). bEnd.3 cells were grown on
Transwell membrane inserts and were exposed to normal glu-
cose, low glucose, or low glucose with 100 ng/ml VEGF for
the indicated times. Briefly, 1.5 ml of culture medium was
added to the abluminal chamber and 0.5 ml was loaded to
the luminal chamber. One hour prior to starting the experi-
ment, 100 μg/ml Na-F (5 μl) in PBS was added to the luminal
chamber. After incubation for 60 min, the samples were col-
lected from the abluminal chamber. Na-F flux was determined
with a fluorescence multi-well plate reader (Ex (λ) 485 nm;
Em (λ) 530 nm). Cell-free samples with no added Na-F served
as controls.
Immunofluorescence
Cultured bEnd.3 cells on glass cover slips were fixed with 4%
paraformaldehyde for 30 min and permeabilized with 0.2 %
Triton X-100 in PBS for 15 min at RT. After washing with
PBS three times, the cells were blocked with 5 % goat serum
in PBS for 30 min. Subsequently, the cells were incubated
with primary antibodies against claudin-5 (1:100,
Invitrogen), ZO-1 (1:100, Invitrogen), and occludin (1:100,
Invitrogen) at RT for 2 h, followed bywashing four times with
PBS. Cells were incubated with secondary antibodies (anti-
mouse or anti-rabbit Alexa Fluor 488 (1:1000)) for 1 h at RT.
Fig. 1 Time-course of the changes in paracellular permeability of bEnd.3
cells after exposure to various concentrations of hypoglycemia during a
24-h period. bEnd.3 cells were plated in a monolayer with Na-F applied.
Na-F was evaluated following treatment with 5.5 mM (control) or 0, 0.5,
or 1 mMover 1, 3, 6, 12, and 24 h. Data are expressed as the percentage of
the time-matched control value. Data are expressed as the mean ± SEM.
N=4. * P<0.05, ** P<0.01
Fig. 2 Effects of hypoglycemia
on TJ proteins in bEnd.3 cells.
Confluent bEnd.3 monolayers
were exposed to 0 mM (a),
0.5 mM (b), 1 mM (c), or 5.5 mM
(d, control) glucose for 1, 3, 6, 12,
or 24 h. Representative blots for
ZO-1, occludin, claudin-5, and β-
actin are shown. Summary plots
of ZO-1 (e), occludin (f), and
claudin-5 (g) expression, includ-
ing densitometric reading of the
corresponding protein blots, are
shown. Data are expressed as the
mean ± SEM. N=3. * P<0.05, **
P<0.01
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Cells stained without primary antibodies served as negative
controls. Nuclei were stained with 1 μg/ml DAPI for 5 min.
The cells were washed thoroughly with PBS and mounted in
fluorescent mounting medium for analysis under a confocal
microscope.
Lactate dehydrogenase (LDH) assay
Following exposure to normal or hypoglycemic media, with
or without 100 ng/ml VEGF, supernatants were collected, and
LDH release was determined using an LDH assay kit
(Beyotime, China) according to the manufacturer’s
guidelines.
Statistical analyses
All data were expressed as the mean ± SEM. An ANOVAwas
used to analyze the data, and a P-value of less than 0.05 was
considered statistically significant.
Results
Effect of hypoglycemia on endothelial permeability
To determine the effect of hypoglycemia on endothelial per-
meability, confluent bEnd.3 cell monolayers were incubated
with varying glucose concentrations for 0 to 24 h, and the Na-
F permeability was analyzed using a Costar Transwell system
(Corning, USA) based on a previous protocol (Dohgu et al.
2004). As shown in Fig. 1, Compared with 5.5 mM glucose,
0 mM glucose increased the Na-F permeability by 28.1, 30.8,
34.3, 41.1, and 56.3 % at 1, 3, 6, 12, and 24 h, respectively.
Compared with 5.5 mM glucose, 0.5 and 1 mM glucose in-
creased the Na-F permeability at 6, 12, and 24 h (by 30.5,
35.3, and 46.6 %, respectively; 21.2, 29.1, and 37 %, respec-
tively) when compared with 5.5 mM glucose. 0 mM glucose
caused significant increase in endothelial permeability after
1 h, while 0.5 and 1 mM glucose increased permeability sig-
nificantly after 6 h. Besides, lower glucose concentrations led
to a greater increase in paracellular permeability than higher
glucose concentrations after 6, 12 or 24 h treatment.
Hypoglycemia increased brain endothelial permeability
time- dependently and glucose concentration-dependently.
Effect of hypoglycemia on the expression of claudin-5, ZO-1,
and occludin in bEnd.3 cells
Tight junctions integrity is a hallmark of brain edema progres-
sion in pathological conditions such as stroke (Jiao et al.
2011). It has been shown that TJ proteins, including occludin,
ZO-1, and claudin-5, have an important role in the integrity of
the BBB (Sandoval and Witt 2008). To investigate whether
these proteins have a major role in hypoglycemia, western blot
and immunofluorescence analyses were performed to detect
the protein expression levels. As shown in Fig. 2, western blot
analysis revealed that hypoglycemia induced a time- and glu-
cose dose-dependent decrease in claudin-5 protein levels.
However, hypoglycemia did not significantly change ZO-1
and occludin expression compared to the control (5.5 mM
glucose). Furthermore, as shown in Fig. 3, immunofluores-
cence imaging confirmed that hypoglycemia did not alter the
localization of claudin-5, ZO-1, and occludin after 6, 12, or
24 h treatment, although occludin is displayed diffuse cyto-
plasmic localization in bEnd.3 (data not shown). These results
were consistent with the observed hypoglycemia-induced
Fig. 3 Effects of hypoglycemia on the expression and distribution of
claudin-5 and ZO-1 in bEnd.3 cells. Confluent bEnd.3 cell monolayers
were exposed to 0.5 mM conditioned medium for 0 (control), 6, 12, and
24 h. Cultures were then stained with claudin-5 (red), ZO-1 (red) and
DAPI (nuclear, blue) to examine protein expression, distribution, and cell
morphology changes. N=3
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permeability increase in the endothelial monolayer. These data
suggested that disruption of claudin-5 may increase BBB
permeability.
Exogenous VEGF ameliorates hypoglycemia-induced brain
endothelial cells dysfunction
Since TJ-mediated regulation of endothelial permeability is
vital to BBB integrity, we assessed the effect of exogenous
VEGF (100 ng/ml) on permeability in bEnd.3 cells under
hypoglycemic conditions by measuring the ability of Na-F
to cross the cell monolayer 24 h after 0.5 mM glucose treat-
ment. As shown in Fig. 4a, a 24 h exposure to 0.5 mM glucose
in presence of VEGF decreased the Na-F permeability by
30.8 % compared with 0.5 mM glucose, suggesting the pres-
ence of VEGF significantly decreased the enhanced endothe-
lial permeability caused by hypoglycemia.
In order to investigate whether VEGF modulates the dis-
ruption of TJ proteins in hypoglycemic conditions, we
assessed the expression levels of claudin-5, occludin, and
ZO-1. Figure 4b and c showed that the decrease in claudin-5
was improved under hypoglycemia in presence of VEGF.
Western blot analysis revealed no change in the expression
of ZO-1 and occludin in bEnd.3 cells treated with VEGF.
Overall, these results suggested that VEGF has a beneficial
effect on endothelial cells during hypoglycemic stress.
Effect of exogenous VEGF on survival of bEnd.3 cells
under hypoglycemic conditions
Endothelial cell death can augment BBB permeability
(Engelhardt et al. 2014). Application of VEGF enhances cell
survival and protects neurons against ischemic injury
(Nishijima et al. 2007). We firstly assessed whether long-
Fig. 4 Effects of VEGF on hypoglycemia-induced paracellular perme-
ability and TJ proteins. (a) Effect of VEGF (100 ng/ml) on cell perme-
ability of cells exposed to 0.5 and 5.5 mM glucose for 24 h. (b) Effects of
VEGF on TJ protein levels during hypoglycemia for 24 h in bEnd.3 cells.
Representative TJ Western blots are shown following treatment with 0.5
or 5.5 mM glucose for 24 h with the presence of 100 ng/ml VEGF.
Summary plots of claudin-5 (c), occludin (d), and ZO-1 (e) are shown
following densitometric analysis of the corresponding protein blots. Data
are expressed as the mean ± SEM. N=3. * P<0.05, ** P<0.01
Metab Brain Dis (2015) 30:999–1007 1003
term hypoglycemia can induce bEnd.3 cell damage. Figure 5a
showed that bEnd.3 cell viability decreased progressively af-
ter 24 h incubation with 0 and 0.5 mM glucose medium. To
further examine the effect of VEGF on hypoglycemia-induced
cell death, bEnd.3 cells were exposed to hypoglycemia in
presence of VEGF (100 ng/ml). Figure 5b showed that a
24 h exposure to 0.5 mM glucose in presence of VEGF de-
creased cell death by 30.5 % compared with 0.5 mM glucose,
suggesting the presence of VEGF significantly reduced cell
death from hypoglycemia.
Hypoglycemia in presence of VEGF highly induces
the expression of Glut-1 and Bcl-2 in endothelial cells
Apoptosis of brain endothelial cells following injury is related
to downregulation of constitutively expressed anti-apoptotic
factors, which is known to further promote BBB breakdown
(Nag et al. 2005). To understand the underlying mechanisms
of VEGF-mediated protection against hypoglycemia, we
analyzed Glut-1 and Bcl-2 protein levels by western blot in
response to VEGF during hypoglycemia. We found that Glut-
1 and Bcl-2 levels in bEnd.3 cells increased in a dose-
dependent manner following 24-h VEGF treatment under hy-
poglycemic conditions. No significant changes in Glut-1 and
Bcl-2 were observed in response to VEGF stimulation when
cells were grown in normal glucose medium (Fig. 6). These
findings suggested that VEGF upregulates Glut-1 and Bcl-2
protein expression under hypoglycemic conditions. These da-
ta supported a mechanism in which VEGF protects cerebral
endothelial cells against hypoglycemia by decreasing
hypoglycemia-induced apoptosis and promoting the transfer
of glucose.
Fig. 5 Effects of hypoglycemia and VEGF treatment on cell viability. (a)
Cells were maintained in 5.5 mM glucose (control) or 0, 0.5 and 1 mM
glucose for the indicated times. The results are given as a percent relative
to the control. (b) VEGF (100 ng/mL) was added to cultures at the onset
of exposure to 0.5 and 5.5 mM (control) mM glucose medium for 24 h.
Cell viability was determined by the LDH assay. Data are expressed as
mean ± SEM. N=3. * P<0.05, ** P<0.01
Fig. 6 Dose-dependent effects of VEGF on the Glut-1 and Bcl-2 during
hypoglycemia in bEnd.3 cells. Confluent bEnd.3 cells were treated with
5.5 mM (control) glucose and 0.5 mM glucose for 24 h in the absence or
presence of different concentrations of VEGF (0, 10, 50, and 100 ng/mL).
(a) Representative Western blots of Glut-1 and Bcl-2 with β-actin as a
protein loading control. Summary plots of Bcl-2 (b) and Glut-1 (c) with
densitometric analyses of the corresponding protein blots. Data are
expressed as mean ± SEM. N=3. * P<0.05, ** P<0.01
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Discussion
The loss of TJs among adjacent endothelial cells that reg-
ulate endothelial permeability (Liu et al. 2012) is the main
factor contributing to brain edema. Many studies have
demonstrated that claudins, but not occludins, are the ma-
jor proteins involved in TJ formation (Jia et al. 2014;
Haseloff et al. 2014), which is essential for maintaining
BBB structure. For example, claudin-5 deletion resulted in
a size-selective increase in permeability (Stamatovic et al.
2008). Further, claudin-5-deficient mice also displayed an
altered BBB with higher permeability (Luissint et al.
2012). It has been shown that hypoxia causes degradation
of occludin, ZO-1, ZO-2, and claudin-3 (González-
Mariscal et al. 2011; Witt et al. 2003). We hypothesized
that altered expression of TJ proteins might contribute to
increased paraendothelial permeability during hypoglyce-
mia. In the present study, we induced hypoglycemic injury
in brain endothelial cells to evaluate the effect of hypo-
glycemia on TJ proteins. Our data indicated that hypogly-
cemia disrupted claudin-5 expression, without affecting the
translocation of claudin-5, and increased paraendothelial
permeability. The potential mechanisms regulating the
change in claudin-5 expression is still unclear, although
we speculate that it is related to glucose depletion during
hypoglycemia.
Previous studies have confirmed that hypoglycemia in-
duces rapid upregulation of VEGF expression, and that
VEGF mediates the rapid adaptation of the brain to hypogly-
cemia (Oltmanns et al. 2008).While several studies have dem-
onstrated that VEGF causes increased BBB permeability
(Argaw et al. 2012; Feng et al. 2011), others have shown that
administration of VEGF intracerebroventricularly protects the
brain against focal ischemia without increasing BBB perme-
ability (Kaya et al. 2005). The specific mechanism of the
VEGF-induced increase in BBB permeability is controversial.
Plate suggested that VEGF plays a role in the protection and
maintenance of endothelial cells (Plate 1999). To assess
whether application of VEGF has a protective effect on endo-
thelial cells during hypoglycemia, we detected the
paraendothelial permeability, TJ-associated protein expres-
sion, and endothelial cell viability. We found that long-term
VEGF treatment decreased endothelial permeability follow-
ing hypoglycemic injury. These results appeared to contradict
data that suggests VEGF plays a vital role in brain edema.
However, analysis of the effect of VEGF on barrier dysfunc-
tion in vitro revealed that VEGF induces transient and revers-
ible permeability in cultured brain endothelial cells (Senger
et al. 1983). Our findings suggest that VEGF may prevent
BBB disruption during hypoglycemia by inhibiting the deg-
radation of claudin-5. However, the exact mechanisms of
VEGF-induced claudin-5 expression are not completely
understood.
VEGF, a potent mediator of angiogenesis, is a candidate
hormone for facilitating glucose passage across the BBB un-
der critical conditions. VEGF has also been shown to enhance
glucose transport by increasing Glut-1 expression, which is an
ideal target to supply much needed glucose required to meet
cellular metabolic requirements (Sone et al. 2000). During
hypoglycemia, Glut-1 gene and protein expression levels in-
crease in vivo (Sahin et al. 2013), thereby increasing BBB
sugar transport capacity. Thus, VEGFmay protect the glucose
supply in the brain by increasing the protein expression of
Glut-1. In the present study, Glut-1 protein levels were signif-
icantly increased in hypoglycemic cells treated with VEGF
compared to untreated hypoglycemic cells. Moreover, several
animal studies have suggested that VEGF reduces cellular
damage in ischemia and hypoxia injury, and that Bcl-2, an
anti-apoptotic protein, can be induced by VEGF (Lladó et al.
2013). We found the Bcl-2 protein levels in VEGF-treated
hypoglycemic cells were significantly increase compared to
untreated hypoglycemic cells. The overall increase of Bcl-2
protein was observed under hypoglycemic conditions in the
presence of VEGF, suggesting that VEGF is an endothelial
cell survival factor. Further, Akt activation by PI3-kinase has
been shown to cause increases in VEGF expression in some
cell types (Pore et al. 2004; Liu et al. 2006), and has been
shown to protect against cell death (Byeon et al. 2010). In
brain microendothelial cells, Akt inhibits apoptosis and en-
hances cell survival (Zhou et al. 2013). Thus, the protective
effect of VEGF against hypoglycemia is mediated in part by
the PI-3 K/Akt pathway. This was confirmed by an LDH assay
that was used to measure cell death. No significant changes in
Glut-1 and Bcl-2 were observed in response to VEGF stimu-
lation when endothelial cells were grown in a normal glucose
medium.
In summary, the present study demonstrated that hypo-
glycemia disrupts the BBB by reducing claudin-5 expres-
sion and increasing endothelial cell death, thereby increas-
ing endothelial permeability. VEGF can protect brain en-
dothelial cells against hypoglycemic injury by increasing
Glut 1, Bcl-2, and claudin-5 expression to promote glu-
cose transport, reduce cell death, and prevent BBB disrup-
tion. Although debates continue over the role of VEGF in
hypoglycemia and this study has several limitations, our
findings may provide the basic data required for further
study of hypoglycemia.
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